Theravance Biopharma (TBPH) Free Cash Flow Growth (3y) (2016 - 2026)
Theravance Biopharma (TBPH) Free Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.97 Bn | 466.18 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.05 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.42 Bn | 959.66 Mn | 31.42% |
| 10 | Theravance Biopharma | 866.36 Mn | 471.69 Mn | - | 100.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100.22% |
| Dec 31, 2025 | -28.28% |
| Sep 30, 2025 | 26.64% |
| Jun 30, 2025 | 152.08% |
| Mar 31, 2025 | 53.76% |
| Dec 31, 2024 | 70.58% |
| Sep 30, 2024 | 51.78% |
| Jun 30, 2024 | 55.43% |
| Mar 31, 2024 | 75.05% |
| Dec 31, 2023 | 71.50% |
| Sep 30, 2023 | 68.35% |
| Jun 30, 2023 | 37.98% |
| Mar 31, 2023 | 39.92% |
| Dec 31, 2022 | 41.49% |
| Sep 30, 2022 | 28.29% |
| Jun 30, 2022 | 32.66% |
| Mar 31, 2022 | 31.65% |
| Dec 31, 2021 | 7.21% |
| Sep 30, 2021 | 2.95% |
| Jun 30, 2021 | 7.07% |